Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. METHODS: In this random...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, Cheadle, Jeremy P
Formato: Artigo
Idioma:Inglês
Publicado em: Lancet Publishing Group 2011
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3159415/
https://ncbi.nlm.nih.gov/pubmed/21641636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60613-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados